Novel microtubule-interacting phenoxy pyridine and phenyl sulfanyl pyridine analogues for cancer therapy.
Current microtubule inhibitory agents used in the clinic to treat cancer have severe side effects, and development of resistance is frequent. We have evaluated the antitumor effect of a novel 30-compound library of phenoxy pyridine and phenyl sulfanyl pyridine derivatives. MTT assays revealed that, of all 30 compounds tested, compounds 2 and 3 showed the largest decrease in proliferation (low muM range) against Panc1 and HS766T human pancreatic cancer cells. Flow cytometry experiments with MCF7 breast cancer cells showed a G2/M arrest comparable to that of colcemid. Immunofluorescence staining demonstrated complete disappearance of intracellular microtubules. Tubulin assembly assays, however, showed a dose-dependent decrease in tubulin assembly with compound 3 that seemed limited to about 50% of the control reaction. With compound 2 treatment, there was only a delay in the onset of assembly, with no effect on the extent of the reaction. Taken together, our results show that these novel microtubule inhibitors have promising anticancer activity and can be potentially used to overcome paclitaxel resistance in the clinical setting.
Anchoori
Ravi Kumar
RK
Division of Chemical Therapeutics, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA.
Kortenhorst
Madeleine Susanne Quirine
MS
Hidalgo
Manuel
M
Sarkar
Taradas
T
Hallur
Gurulingappa
G
Bai
Ruoli
R
Diest
Paul J Van
PJ
Hamel
Ernest
E
Khan
Saeed R
SR
D000970:Antineoplastic Agents / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D006801:Humans; D008870:Microtubules / Q000737:chemistry* / Q000187:drug effects; D015394:Molecular Structure; D009369:Neoplasms / Q000188:drug therapy*; D011725:Pyridines / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use*; D054852:Small Molecule Libraries; D013237:Stereoisomerism; D013329:Structure-Activity Relationship; D014404:Tubulin / Q000187:drug effects
D000970:Antineoplastic Agents; D011725:Pyridines; D054852:Small Molecule Libraries; D014404:Tubulin
J Med Chem. 2006 Apr 6;49(7):2357-60
16570932
J Appl Toxicol. 1993 Jan-Feb;13(1):67-8
8440876
Proc Natl Acad Sci U S A. 1983 May;80(10):2926-30
6574461
Cell Biochem Biophys. 2003;38(1):1-22
12663938
Mol Cancer Ther. 2007 May;6(5):1509-16
17483439
Chem Pharm Bull (Tokyo). 1991 Sep;39(9):2308-15
1804543
Chem Pharm Bull (Tokyo). 1999 Mar;47(3):430-3
10212393